CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico

Journal of Clinical Pharmacology
Martha Sosa-MacíasIsmael Lares-Asseff

Abstract

Although the drug-metabolizing enzyme CYP2D6 has been studied extensively in subjects of differing ethnicities, limited CYP2D6 pharmacogenetic data are available for the Amerindian population and Mestizos of Mexico. Dextromethorphan hydroxylation phenotype was studied in Tepehuano Amerindian (n = 58) and Mestizo (n = 88) subjects, and 195 individuals (85 Tepehuano Amerindians and 110 Mestizos) were genotyped by polymerase chain reaction-restriction fragment length polymorphism methods to identify the frequencies of the CYP2D6*3, *4, *6, and *10 alleles. Tepehuano Amerindian subjects lacked the poor metabolizer (PM) phenotype, whereas in Mestizos the PM phenotype frequency was 6.8%. The CYP2D6*3, *6, and *10 alleles were not found in Tepehuano Amerindians. The CYP2D6*4 allele had a low frequency (0.006) in this Amerindian group. In the Mestizo group, the CYP2D6*3, *4, and *10 alleles had frequencies of 0.009, 0.131, and 0.023, respectively. The CYP2D6*6 allele was not found in Mestizos. The genotype-phenotype association was strongly statistically significant (r(2) = .45; P = .005) in Mestizos. The Tepehuano population was found to have a low phenotypic and genotypic CYP2D6 diversity and differed from other Amerindian groups. On...Continue Reading

References

Sep 1, 1991·Clinical Pharmacology and Therapeutics·F J Gonzalez, U A Meyer
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·R H WardS Pääbo
Jul 1, 1991·Diabetes Care·C L HanisW J Schull
Jan 1, 1990·Pharmacology & Therapeutics·M Eichelbaum, A S Gross
Jan 1, 1989·European Journal of Clinical Pharmacology·K Brøsen, L F Gram
Oct 1, 1986·American Journal of Physical Anthropology·R LiskerL Buentello
Dec 1, 1988·British Journal of Clinical Pharmacology·Y HoraiK Ishikawa
Oct 8, 1987·Nature·J M Diamond
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·I JohanssonM Ingelman-Sundberg
Jun 1, 1996·Pharmacogenetics·A K DalyU M Zanger
May 26, 1999·Clinical Pharmacology and Therapeutics·T TateishiS Kobayashi
Dec 26, 2001·Clinical Pharmacology and Therapeutics·R MendozaK M Lin
Feb 2, 2002·Clinical Pharmacology and Therapeutics·Agneta WennerholmLars L Gustafsson
Mar 14, 2002·American Journal of Human Biology : the Official Journal of the Human Biology Council·Ricardo M Cerda-FloresRanajit Chakraborty
Aug 2, 2002·Clinical Pharmacology and Therapeutics·Andrea GaedigkJ Steven Leeder
Jan 31, 2003·Annals of Human Genetics·B MoreraR Marin-Rojas

❮ Previous
Next ❯

Citations

Nov 16, 2011·European Journal of Clinical Pharmacology·Pedro DoradoAdrián Llerena
Feb 26, 2010·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·Patricia NeafseyBabasaheb Sonawane
Jul 7, 2011·Genetic Testing and Molecular Biomarkers·Laura N RiccardiSusi Pelotti
Mar 12, 2011·Pharmacogenomics·Alejandra V ContrerasIrma Silva-Zolezzi
Feb 19, 2014·Pharmacogenomics·Blanca Patricia Lazalde-RamosAdrián Llerena
Oct 16, 2014·Expert Opinion on Drug Metabolism & Toxicology·Adrián LLerenaEduardo Tarazona-Santos
May 6, 2015·Pharmacogenomics·Yadira Xitlalli Perez-ParamoAugusto Rojas-Martinez
May 16, 2014·Disease Markers·Dealmy Delgadillo GuzmánIsmael Lares Asseff
Dec 17, 2014·Pharmacogenomics·Marisol López-LópezAdrián LLerena
Feb 2, 2018·Journal of Personalized Medicine·Lindsay M HendersonKenneth E Thummel
Dec 8, 2010·The Pharmacogenomics Journal·A LlerenaL R Calzadilla
Sep 6, 2018·Omics : a Journal of Integrative Biology·María-Eugenia G NaranjoUNKNOWN CEIBA-Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF
Oct 24, 2007·Pharmacology·Octavio D Reyes-HernándezGuillermo Elizondo
Sep 26, 2014·Drug Metabolism and Drug Interactions·Miguel Angel Chiurillo
Oct 17, 2013·Drug Metabolism and Drug Interactions·Patricia Cuautle-RodríguezJuan Molina-Guarneros
Dec 10, 2014·Drug Metabolism and Drug Interactions·Carolina Céspedes-GarroUNKNOWN CEIBA Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF
Oct 23, 2013·Drug Metabolism and Drug Interactions·Martha Sosa-Macías, Adrián Llerena
Jun 22, 2013·Drug Metabolism and Drug Interactions·Fernando de AndrésUNKNOWN CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEFa
Aug 19, 2020·Pharmacogenomics·Rangel-Méndez Jorge-AarónMoo-Puc Rosa Esther
Oct 31, 2020·Pharmacogenomics·Alba P SarmientoUNKNOWN CEIBA Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF
Aug 5, 2008·Genome Research·Gerardo Jimenez-SanchezSantiago March

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.